LCN2: Potential Targets for Cancer via Ferroptosis-Related Pathways
- 1Department of Gynecology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China
Abstract
Lipocalin 2 (LCN2) was initially identified as a lipid carrier protein, and recent studies have revealed it acts as a multifunctional regulator of cancer progression that is closely associated with ferroptosis. Ferroptosis is a newly discovered form of programmed cell death, characterized by alterations in intracellular iron content and lipid peroxidation levels, and disruption of antioxidant defense systems. Given the close connection between ferroptosis and multiple diseases, particularly cancer, investigation into the mechanisms underlying ferroptosis has become a key research direction in recent years. Recently, a growing body of research has demonstrated that LCN2 plays important roles in ferroptosis regulation and exhibits context-dependent effects across different malignant tumors, while the molecular basis behind this phenomenon remains not fully understood. Given these findings, LCN2 is considered a promising therapeutic target for tumor progression. Accordingly, this review summarize how LCN2 interacts with molecules in ferroptosis-related pathways, its diverse roles within the same cancer, and its regulatory functions in the tumor microenvironment. Additionally, this review discusses the current clinical application of LCN2 as a biomarker and therapeutic target, Thus, this review aims to elucidate the role of LCN2 in cancer progression and its immense potential as a therapeutic target. It is hoped that these research findings will be translated into clinical cancer treatment strategies.
Related
- Peripheral Blood Mononuclear Cell Expression Profile of Proliferation-, Ferroptosis-, and Immune-Related Targets in Breast Cancer.
- Natural compounds regulating MAPK-related signaling pathways: potential intervention strategies for gastric cancer
- Punicalagin Alleviates Diabetic Kidney Injury: Potential Involvement of SESN2-Related Mitophagy and Changes in Pyroptosis-/Ferroptosis-Related Indicators
- Multi-Target Regulation of Diabetic Nephropathy by Alkaloids: Molecular Targets, Signaling Pathways and Therapeutic Potential
- M2 macrophage-derived exosomes and miR-132-3p promote gastric cancer cell aggressiveness and attenuate ferroptosis-related changes
BibTeX
@article{zhang2026lcn2,
title = {{LCN2: Potential Targets for Cancer via Ferroptosis-Related Pathways}},
author = {Juan Zhang and Ying Chen},
journal = {Oncology Research},
year = {2026},
month = oct,
doi = {10.32604/or.2026.090752},
url = {https://doi.org/10.32604/or.2026.090752},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - LCN2: Potential Targets for Cancer via Ferroptosis-Related Pathways
AU - Juan Zhang
AU - Ying Chen
PY - 2026
DA - 2026/10/28
JO - Oncology Research
DO - 10.32604/or.2026.090752
UR - https://doi.org/10.32604/or.2026.090752
AB - Lipocalin 2 (LCN2) was initially identified as a lipid carrier protein, and recent studies have revealed it acts as a multifunctional regulator of cancer progression that is closely associated with ferroptosis. Ferroptosis is a newly discovered form of programmed cell death, characterized by alterations in intracellular iron content and lipid peroxidation levels, and disruption of antioxidant defense systems. Given the close connection between ferroptosis and multiple diseases, particularly cancer, investigation into the mechanisms underlying ferroptosis has become a key research direction in recent years. Recently, a growing body of research has demonstrated that LCN2 plays important roles in ferroptosis regulation and exhibits context-dependent effects across different malignant tumors, while the molecular basis behind this phenomenon remains not fully understood. Given these findings, LCN2 is considered a promising therapeutic target for tumor progression. Accordingly, this review summarize how LCN2 interacts with molecules in ferroptosis-related pathways, its diverse roles within the same cancer, and its regulatory functions in the tumor microenvironment. Additionally, this review discusses the current clinical application of LCN2 as a biomarker and therapeutic target, Thus, this review aims to elucidate the role of LCN2 in cancer progression and its immense potential as a therapeutic target. It is hoped that these research findings will be translated into clinical cancer treatment strategies.
SN - 0965-0407
SN - 1555-3906
ER -